Abstract: The present invention relates to a method for forming an organic element of an electronic device having at least two different pixel types including a first pixel type (pixel A) and a second pixel type (pixel B), —wherein at least one layer of pixel A is deposited by applying an ink A containing at least one organic functional material A and at least one solvent A by a printing process, —wherein at least one layer of pixel B is deposited by applying an ink B containing at least one organic functional material B and at least one solvent B by a printing process, —wherein at least one organic functional material A and at least one organic functional material B are different, and —wherein at least one solvent A and at least one solvent B are different, characterized in that both inks, ink A and ink B, in addition contain at least one common solvent S, and characterized in that the boiling point of solvent A and the boiling point of solvent B is at least 10° C. lower than the boiling point of the common solvent S.

Abstract: The present invention provides methods for making polysaccharide-protein conjugates in which polysaccharides, typically from bacteria, are conjugated to a carrier protein by reductive amination under conditions which improve conjugation reaction consistency, increase consumption of protein during conjugation reaction, generate conjugates of higher molecular weight, and/or reduce the levels of free cyanide in the conjugate reaction product. The polysaccharide-protein conjugates obtained using these methods are useful for inclusion in multivalent vaccines.

Abstract: The present invention relates to a scalable process for the purification of human cytomegalovirus particles from cell culture medium. In particular, the process involves a two step chromatography process starting with an anion exchange chromatography step followed by a polishing chromatography step selected from mixed mode chromatography or cation exchange chromatography.

Abstract: The present invention relates to compounds and pharmaceutically acceptable salts or solvates thereof for use in the treatment or prevention of fascioliasis. Some of these compounds are novel per se and also have activity as inhibitors of Schistosoma growth. The invention also relates to pharmaceutical compositions comprising such novel compounds, salts or solvates and to the use of such novel compounds as medicaments, in particular in the treatment or prevention of schistosomiasis, also known as bilharzia.

Abstract: The present invention provides a method for producing a novel amorphous silicon sacrifice film and an amorphous silicon forming composition capable of filling trenches having a high aspect ratio to form an amorphous silicon sacrifice film that is excellent in affinity with a substrate. A method for producing an amorphous silicon sacrifice film, comprising (i) polymerizing a cyclic polysilane comprising 5 or more silicon or a composition comprising the cyclic polysilane by light irradiation and/or heating to form a polymer having a polysilane skeleton, (ii) applying an amorphous silicon forming composition comprising said polymer having a polysilane skeleton, polysilazane and a solvent above a substrate to form a coating film, and (iii) heating the coating film in a non-oxidizing atmosphere.

Abstract: A method is described for producing a pneumococcal capsular polysaccharide protein conjugate in which one or more activated pneumococcal polysaccharides of particular pneumococcal serotypes and carrier protein are separately lyophilized, the separately lyophilized polysaccharides and carrier protein are separately reconstituted in an organic solvent, and the reconstituted polysaccharide and carrier protein are then combined together by Tee-mixing and conjugated together to produce polysaccharide carrier protein conjugates. A plurality of conjugates, each comprising polysaccharides of a particular serotype, may be used to produce multivalent pneumococcal immunogenic compositions having a combination of conjugates for use in vaccines.

Abstract: The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant.

Abstract: The present invention relates to efficient synthetic processes useful in the preparation of Compound A, a BTK inhibitor of Formula (I): or a pharmaceutically acceptable salt thereof, including the preparation of intermediates used to make Compound A or a pharmaceutically acceptable salt thereof.

Abstract: A method can treat a patient suffering from at least one of fibrosis and a fibrotic disorder. The method includes administering a therapeutically effective amount of an anti-?v integrin antibody DI17E6, or a biologically active variant or modification thereof, to the patient.

Abstract: Provided are compounds of Formula I, Formula Ia and Formula Ib and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, Formula Ia and Formula Ib, pharmaceutical compositions comprising compounds of Formula I, Formula Ia and Formula Ib, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), hepatic fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I, Ia and Ib and the pharmaceutically acceptable salts, esters, and prodrugs thereof, to a patient in need thereof.

Abstract: The present invention relates to a new class of dielectric polymer material, which is particularly suitable for the manufacturing of electronic devices. The dielectric polymer material is formed by reacting bismaleimide compounds and shows an advantageous well-balanced profile of favorable material properties. The bismaleimide compounds have an oligomeric structure with an oligoamide extended repeating unit in the middle part of the molecule and maleimide groups at each terminal end of the molecule. There is further provided a method for forming said dielectric polymer material. Beyond that, the present invention relates to the dielectric polymer material and to an electronic device comprising the same.

Abstract: A functional cell-based potency assay for measuring the biological activity of IL-2 mutants with biased activity for the IL-2 receptor beta-gamma complex is described. In particular, the present invention relates to a Kit225 cell line that lacks expression of the IL-2 receptor alpha and its use in said functional cell-based potency assay.

Abstract: The present invention describes dibenzofuran derivatives substituted by electron-deficient heteroaryl groups, and electronic devices, especially organic electroluminescent devices, comprising these compounds as triplet matrix materials.

Abstract: Crystalline monosodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solvates thereof, their use as pharmaceuticals, as well as processes of obtaining the same.

Abstract: A method for controlling the state of two or more liquid crystal-based switchable windows includes in a first step providing correction data which define a relationship between a state signal and an output voltage level. The correction data is provided for each of the switchable windows and the state of the switchable windows may be adjusted according to the state signal between a minimum and maximum level. In a subsequent step, the state signal is provided which defines the desired state of one or more selected switchable windows. In a further step, a required voltage level is determined for setting the desired state based on the state signal and the respective correction data for each of the one or more selected windows. In a subsequent step d), an AC output voltage is generated having the required voltage level for each of the one or more selected windows.

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

Abstract: The present disclosure provides transaminase enzymes having improved properties and are capable of reducing (1S,5R)-6,8-dioxabicyclo[3.2.1]octan-4-one with high selectivity. Also provided are polynucleotides encoding the transaminase enzymes, host cells capable of expressing the transaminase enzymes, and methods of using the transaminase enzymes to synthesize (1S,4R,5R)-6,8-dioxabicyclo[3.2.1]octan-4-amine.

Abstract: Method for selecting at least one viscosity changing excipient for a formulation containing at least one unknown protein via a computer includes providing a data set that describes the viscosity of several known formulations containing at least one protein and optionally at least one viscosity changing excipient; generating representations of at least one excipient; using a Machine Learning Model executed on the computer to recognize patterns in the data set to evaluate the viscosity changing effect of the viscosity changing excipient to a new formulation containing at least one unknown protein by applying the recognized patterns on provided data of the unknown protein; selecting the at least one excipient according to an acquisition criterion and applying the excipient to the unknown protein, wherein the provided data of the at least one unknown protein describe the viscosity of a protein composition containing the at least one unknown protein.

Abstract: A liquid crystal medium comprising one or more compounds of formula PT and one or more compounds of formula GF and/or UI in which the occurring groups and parameters have the meanings defined in claim 1. Also, high-frequency components comprising these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tunable filters, tunable metamaterial structures, and electronic beam steering antennas, e.g. phased array antennas.

Abstract: The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.